Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo

Next Previous
Search
Trial Profile

Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Hydroxychloroquine (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms EPICOS

    • Most Recent Events

    • 01 Jan 2023 Results assessing the effect of hydroxychloroquine and Tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis on COVID-19 risk published in the Clinical Microbiology and Infection
    • 28 Aug 2022 Results assessing the effect of Tenofovir Disoproxil Fumarate/Emtricitabine, Hydroxychloroquine, and their combination as pre-exposure prophylaxis on the risk of symptomatic COVID-19, presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
    • 04 Sep 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top